Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

EAST HANOVER, N.J., July 8, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC)(1,2,6). This study, the largest prospective clinical trial to date in this patient population, is being presented on Saturday, July 9 at the International TSC Research Conference in Washington, D.C.

Currently, Afinitor is approved in the US for the following indication: to treat patients with SEGA associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical intervention. The effectiveness of everolimus is based on an analysis of change in SEGA volume. Additionally, the indication states, clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown(7).

Tuberous sclerosis complex affects approximately 25,000 to 40,000 people in the US and one to two million people worldwide, and is associated with a variety of resulting disorders including seizures, swelling in the brain (hydrocephalus), developmental delays and skin lesions(2,6). Also known as tuberous sclerosis (TS), TSC is a genetic disorder that may cause non-cancerous tumors to form in vital organs and can affect many different parts of the body, most commonly the brain and kidney(6,8). Signs and symptoms of TSC vary depending on which system and which organs are involved(6). SEGAs occur in up to 20% of patients with TSC. In countries where everolimus is not approved, brain surgery is the only treatment option for patients with growing SEGAs(2).

The 117-patient, randomized, placebo-controlled Phase III EXIST-1 (EXamining everolimus In a Study of TSC) trial met its primary endpoin
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 Transparency Market ... titled " Cancer Diagnostics Market - Global Industry ... " . According to this report, the global cancer ... 7.6% during the forecast period of 2014 to 2020. In ... million and is expected to be worth US$168,649.3 million by ...
(Date:7/28/2015)... BERN, Switzerland , July 28, 2015 /PRNewswire/ ... has accepted for review a Marketing Authorization Application ... linking recombinant coagulation factor IX with recombinant albumin ... episodes in people with Hemophilia B. Upon Swissmedic ... a long-acting treatment option with dosing intervals up ...
(Date:7/28/2015)... Mass. , July 28, 2015  Today, Sekisui ... A compact, affordable and efficient instrument, with a broad ... bring significant benefits to the physicians, office or hospital ... of up to 580 tests/hour with ISE, 72 patient ... and has 36 onboard assays (+3 ISE) to meet ...
Breaking Medicine Technology:Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 2Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 3Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 4Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 3Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 4Sekisui Diagnostics Announces Launch of SK500 Clinical Chemistry System for US Laboratories 2
... BEACH GARDENS, Fla., May 19, 2011 ... over-the-counter (OTC) children,s acetaminophen medications, AccuDial Pharmaceutical, ... & Drug Administration (FDA) at the meeting ... Non-Prescription Drugs Advisory Committee meeting on Tuesday, ...
... LOS ANGELES, May 19, 2011 Counting calories is ... pharmacist James LaValle, one of the nation,s leading experts ... our metabolism. In response, one of the ... (NYSE: LTM ), has partnered with LaValle ...
Cached Medicine Technology:AccuDial Recommendations for Safer and Effective Dosing to Pediatric Acetaminophen Advisory Committee 2AccuDial Recommendations for Safer and Effective Dosing to Pediatric Acetaminophen Advisory Committee 3AccuDial Recommendations for Safer and Effective Dosing to Pediatric Acetaminophen Advisory Committee 4Counting Calories Inadequate for Sustained Weight Loss 2
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... Valley Campus have received the Get With The Guidelines®-Stroke Gold Plus Award for ... in patient care and outcomes. , The Get With The Guidelines-Stroke program ...
(Date:7/28/2015)... ... July 28, 2015 , ... A skin cancer screening program offered by ... of A award for “helping to make the world a better place.” , The ... by the American Society of Association Executives. Power of A recognizes organizations annually that ...
(Date:7/28/2015)... ... July 28, 2015 , ... The Triumph Modular, Redefining ... consumer education, resource library, floor plans, educational blog and wide use of imagery. ... regular posts with valuable links to useful reports by industry experts. Comments are ...
(Date:7/28/2015)... New Port Richey, FL (PRWEB) , ... July ... ... from Brown University and The Miriam Hospital examines outcomes for inmates who continued ... and found the latter group was more likely to relapse to opiate use ...
(Date:7/28/2015)... ... July 28, 2015 , ... The Denver Foundation ... Philanthropy Reframed and Exhibited,” a photographic and narrative exploration of African American giving, ... Five Points neighborhood. , Denver is one of only ten cities to host ...
Breaking Medicine News(10 mins):Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 2Health News:Jordan Valley Medical Center and Jordan Valley Medical Center West Valley Campus Receive Stroke Award 3Health News:ASDS Skin Cancer Program Honored 2Health News:ASDS Skin Cancer Program Honored 3Health News:Triumph Modular Launches Refreshed Modular Building Industry Website 2Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 2Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 3Health News:Novus Medical Detox Center Analyzes Methadone Study Findings and Implications for Opiate Abuse Treatment 4Health News:"The Soul of Philanthropy Reframed and Exhibited” Comes to Denver 2
... News) -- Electrical stimulation of the brain can bring ... new, difficult problems, research suggests. Investigators in Australia ... brain,s anterior temporal lobes were three times more likely ... problem than participants in a control group. Many ...
... WEDNESDAY, Feb. 2 (HealthDay News) -- A mother,s history of ... having a stroke but also her chances of having a ... that stroke in mothers is associated with heart attacks in ... the Stroke Prevention Research Unit at the University of Oxford, ...
... a rapidly growing population in the United States, account ... cost. Yet more than half of clinical ... conditions, according to a new study by Robert Wood ... Michigan. "These findings are concerning because it ...
... Inflammation is a healthy response in reaction to ... starts in the lungs and builds up to a ... inflammation has been directly associated with heart disease and ... and Professor of Biological Sciences Marcia Newcomer, together with ...
... (February 02, 2011) The International Serious Adverse ... with the HMO Research Network (HMORN) to enroll ... may help predict risk associated with a range ... will diversify the iSAEC methods for developing SAE ...
... thought to be active in killing cells also promotes cellular ... of RIP1 is actually necessary for survival of septic injury, ... potential for developing new treatments for sepsis PROVIDENCE, ... protein that plays a dual role in the liver during ...
Cached Medicine News:Health News:If Mom Had a Stroke, Daughter May Be Prone to Heart Attack 2Health News:If Mom Had a Stroke, Daughter May Be Prone to Heart Attack 3Health News:Older adults often excluded from clinical trials 2Health News:Breathing easy: LSU biochemists offer first 3-D model of asthma-causing inflammation enzyme 2Health News:iSAEC and HMORN to use electronic medical records to research genetics of drug-induced SAEs 2Health News:The 'death switch' in sepsis also promotes survival 2
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... is a wearable CPAP (Continuous Positive Airway ... apnea. The lightweight BreatheX CPAP device (patent ... its built-in, rechargeable battery, and is mobile, ... longer need to be "plugged in to ...
Shandon Paraffin Block Cartons...
The Tissue Cassette Storage Cabinet is made of strong, laminated fiberboard....
Medicine Products: